Active Biotech AB (OSTO:ACTI) 5-Year EBITDA Growth Rate: 11.30% (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OSTO:ACTI Active Biotech AB OSTO:ACTI
28 GF Score
Price kr5.19
! 1 Warning Sign
View Full Analysis

What is Active Biotech AB 5-Year EBITDA Growth Rate?

Active Biotech AB OSTO:ACTI +0.58% 28 5-Year EBITDA Growth Rate is 11.30% as of Mar. 2026. GuruFocus rates OSTO:ACTI with a GF Score™ of 28/100. The stock has 1 warning sign investors should review.

Active Biotech AB's EBITDA per Share for the three months ended in Mar. 2026 was kr-0.33.

During the past 3 years, the average EBITDA Per Share Growth Rate was 30.30% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was 11.30% per year. During the past 10 years, the average EBITDA Per Share Growth Rate was 12.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Active Biotech AB was 46.10% per year. The lowest was -32.50% per year. And the median was 6.35% per year.


Active Biotech AB  (OSTO:ACTI) 5-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.


Active Biotech AB 5-Year EBITDA Growth Rate Related Terms


OSTO:ACTI vs VRTX, REGN, RVMD: 5-Year EBITDA Growth Rate Comparison

For the Biotechnology subindustry, Active Biotech AB's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Active Biotech AB 5-Year EBITDA Growth Rate vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Active Biotech AB's 5-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Active Biotech AB's 5-Year EBITDA Growth Rate falls into.


OSTO:ACTI
28GF Score
Active Biotech AB OSTO:ACTI
5-Year EBITDA Growth Rate is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Active Biotech AB 5-Year EBITDA Growth Rate Calculation

This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

What does a 5-Year EBITDA Growth Rate of 11.30% mean?
Active Biotech AB (OSTO:ACTI) has a 5-Year EBITDA Growth Rate of 11.30% as of Mar. 2026. 5-Year EBITDA Growth Rate is the 5-year average growth rate of EBITDA per share. View historical data for Active Biotech AB and its competitors.
Is Active Biotech AB's 5-Year EBITDA Growth Rate too high?
Active Biotech AB's current 5-Year EBITDA Growth Rate is 11.30%. Overall, Active Biotech AB has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Active Biotech AB's 5-Year EBITDA Growth Rate compare to VRTX and REGN?
Active Biotech AB's 5-Year EBITDA Growth Rate of 11.30% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year EBITDA Growth Rate for a Biotechnology company?
A good 5-Year EBITDA Growth Rate depends on the Biotechnology industry context. However, 5-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year EBITDA Growth Rate mean?
A high 5-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 5-Year EBITDA Growth Rate is the 5-year average growth rate of EBITDA per share. View historical data for Active Biotech AB and its competitors. Active Biotech AB's current 5-Year EBITDA Growth Rate is 11.30%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Active Biotech AB stock overvalued right now?
Active Biotech AB (OSTO:ACTI) has a current 5-Year EBITDA Growth Rate of 11.30%. The current 5-Year EBITDA Growth Rate is 11.30%. Active Biotech AB's overall GF Score™ is 28/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year EBITDA Growth Rate calculated?
5-Year EBITDA Growth Rate is calculated from a company's financial statements. For Active Biotech AB (OSTO:ACTI), the current 5-Year EBITDA Growth Rate is 11.30% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Active Biotech AB Business Description

Other Exchanges 0GQU:UKBTP:Germany
Address Scheelevagen 22, P.O. Box 724, Lund, SWE, 223 63
Active Biotech AB focuses on the research and development of pharmaceuticals products within medical areas including neurodegenerative diseases, autoimmune/inflammatory disease and various forms of cancer. Its project portfolio contains both small molecules that are orally active immunomodulatory agents and antibody based immunotherapy. Its project portfolio includes both small orally active immunomodulatory molecules and antibody-based immunotherapy. Its pipeline products are: Tasquinimod, Laquinimod, and Naptumomab.
28GF Score

Get the complete analysis for OSTO:ACTI

5-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr5.19
Price